Biotech Values

[DewDiligence]

APLS -32%/AH on missed primary endpoint in one of two phase-3 trials in GA (dry AMD):

https://www.globenewswire.com/news-release/2021/09/09/2294782/0/en/Apellis-Announces-Top-Line-Results-from-Phase-3-DERBY-and-OAKS-Studies-in-Geographic-Atrophy-GA-and-Plans-to-Submit-NDA-to-FDA-in-the-First-Half-of-2022.html